← Back to feed

Verici DX

VRCI · AIM · Health Care · mcap £5.1m today

All announcements

All RNS · 52 Key events · 25

01 Oct 26

Capital Access Window - Verici Dx PLC

RNS 9801100 ↗
30 Sep 26

Half-year Results

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its unaudited interim results for the six months ended 30 June 2026 (“H1 2026”).
RNS 9799956 ↗
30 Sep 26

Proposed Fundraise and Capital Access Window

UPON PUBLICATION OF THIS ANNOUNCEMENT, THE INSIDE INFORMATION CONTAINED HEREIN IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
RNS 9799955 ↗
21 Sep 26

Q4 launch of TranscripTx™ genetic test

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it will be launching TranscripTx™, a first-in-class genetic test specifically designed for the transplant community, in Q4 2026.
RNS 9780837 ↗
11 Aug 26

Certified Service Provider agreement with Olink®

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has achieved status as an Olink Certified Service Provider, part of Thermo Fisher's Life Sciences Solutions.
RNS 9714391 ↗
06 Jul 26

Investor presentation

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, will provide a live online presentation relating to the Company's final results announced on 29 June 2026, and recent fundraise, via Investor Meet Company at...
RNS 9653047 ↗
29 Jun 26

Final Results

Final results for the year ended 31 December 2025
RNS 9640388 ↗
24 Jun 26

New York State clinical lab certification received

Nationwide access to Tutivia™ extended with authorisation to all 50 US states completed
RNS 9633213 ↗
12 Jun 26

Result of WRAP Retail Offer

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, confirms, further to the announcements made on 8 June 2026, the result of its WRAP Retail Offer at the Issue Price of 0.35 pence per share.
RNS 9614704 ↗
08 Jun 26

WRAP Retail Offer for up to £200,000

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £200,000 (the "WRAP Retail Offer") through the issue of...
RNS 9605346 ↗
05 Jun 26

Result of Placing & raising gross proceeds c£2.5m

IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR), AS PERMITTED BY UK MAR.
RNS 9605161 ↗
05 Jun 26

Proposed Fundraising via Placing

IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR), AS PERMITTED BY UK MAR.
RNS 9604641 ↗
02 Jun 26

Study validating economic advantages of PTRA test

Study validating economic advantages of PTRA test published
RNS 9596042 ↗
02 Jun 26

AMA grants additional CPT® Code for ProtegaTM

American Medical Association grants Verici Dx additional CPT® Code for ProtegaTM
RNS 9596035 ↗
19 May 26

Clinical study validating PTRA test published

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces the publication of a peer-reviewed clinical validation study of its Pre-Transplant Rejection Assessment ("PTRA") test.
RNS 9574286 ↗
16 Apr 26

Positive Q1 Trading Update

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, provides a trading update demonstrating strong momentum for the three months ended 31 March 2026 (Q1 '26).
RNS 9522428 ↗
31 Mar 26

Directorate Change

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that James McCullough, Non-Executive Director, has resigned from the Board with immediate effect to focus on his role as CEO of Renalytix plc.
RNS 9499235 ↗
05 Feb 26

FY25 Trading Update

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, provides a trading update for the year ended 31 December 2025 ("FY25"), a year of strong growth and commercial progress for the Company.
RNS 9410215 ↗
05 Feb 26

Agreement with BCBS of Illinois for Tutivia™

Agreement with Blue Cross and Blue Shield of Illinois for Tutivia™
RNS 9410085 ↗
12 Nov 25

Completion of CAP accreditation audit

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully completed its second biennial inspection of the Company's clinical laboratory, accredited by the College of American...
RNS 9227785 ↗
06 Nov 25

Provider Participation Agreement with Prime Health

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has signed a Provider Participation Agreement ('the Agreement') with Prime Health Services ('Prime Health'), a dynamic healthcare technology US...
RNS 9215540 ↗
03 Nov 25

Completion of ISO 27001 surveillance audit

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully completed the annual surveillance audit for its ISO 27001:2022 certification.
RNS 9207521 ↗
30 Oct 25

Options revision & Grant of new share options

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that upon the recommendation of the Company's Remuneration Committee, it has repriced certain existing options over ordinary shares of 0.1 pence each...
RNS 9202823 ↗
06 Oct 25

Directorate Change

Verici Dx plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces the appointment to the Board of Aubrey Powell, as Non-executive Director, with immediate effect.
RNS 9151591 ↗
06 Oct 25

Update on Tutivia™ test adoption

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces positive progress in its plans to drive strong Tutivia™ sales growth following the equity fundraise completed in July.
RNS 9151430 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.